U.S. Officials Plead for More Use of Languishing Antibody Drugs
Supply Chain Brain
JANUARY 16, 2021
U.S. health officials are pleading for more use of COVID-19 antibody therapies from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that have been plagued by logistical issues, lack of efficacy data and insufficient reimbursement.
Let's personalize your content